Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $95.54 million. The enterprise value is -$46.98 million.
Important Dates
The next estimated earnings date is Tuesday, December 31, 2024, after market close.
| Earnings Date | Dec 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ORMP has 40.31 million shares outstanding. The number of shares has increased by 2.51% in one year.
| Current Share Class | 40.31M |
| Shares Outstanding | 40.31M |
| Shares Change (YoY) | +2.51% |
| Shares Change (QoQ) | -1.67% |
| Owned by Insiders (%) | 11.08% |
| Owned by Institutions (%) | 12.50% |
| Float | 33.66M |
Valuation Ratios
The trailing PE ratio is 21.65.
| PE Ratio | 21.65 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.08, with a Debt / Equity ratio of 0.00.
| Current Ratio | 27.08 |
| Quick Ratio | 26.99 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.33 |
Financial Efficiency
Return on equity (ROE) is 2.89% and return on invested capital (ROIC) is -4.29%.
| Return on Equity (ROE) | 2.89% |
| Return on Assets (ROA) | -4.12% |
| Return on Capital (ROIC) | -4.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $343,462 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ORMP has paid $2.77 million in taxes.
| Income Tax | 2.77M |
| Effective Tax Rate | 38.65% |
Stock Price Statistics
The stock price has increased by +5.33% in the last 52 weeks. The beta is 1.68, so ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | +5.33% |
| 50-Day Moving Average | 2.38 |
| 200-Day Moving Average | 2.43 |
| Relative Strength Index (RSI) | 47.25 |
| Average Volume (20 Days) | 224,429 |
Short Selling Information
The latest short interest is 299,511, so 0.74% of the outstanding shares have been sold short.
| Short Interest | 299,511 |
| Short Previous Month | 313,896 |
| Short % of Shares Out | 0.74% |
| Short % of Float | 0.89% |
| Short Ratio (days to cover) | 3.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.06M |
| Pretax Income | 10.46M |
| Net Income | 4.47M |
| EBITDA | -12.85M |
| EBIT | -13.06M |
| Earnings Per Share (EPS) | $0.11 |
Full Income StatementBalance Sheet
The company has $142.30 million in cash and $429,000 in debt, giving a net cash position of $142.52 million or $3.54 per share.
| Cash & Cash Equivalents | 142.30M |
| Total Debt | 429,000 |
| Net Cash | 142.52M |
| Net Cash Per Share | $3.54 |
| Equity (Book Value) | 155.52M |
| Book Value Per Share | 3.89 |
| Working Capital | 137.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.92 million and capital expenditures -$10,000, giving a free cash flow of -$7.93 million.
| Operating Cash Flow | -7.92M |
| Capital Expenditures | -10,000 |
| Free Cash Flow | -7.93M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |